honokiol thioether 3k

Honokiol thioether 3k is a **novel semisynthetic honokiol-derived small molecule** bearing a 1,3,4-oxadiazole-containing thioether modification that has been reported in preclinical research as an anticancer lead for **colon cancer**, particularly HCT116 cells. In the cited study, it showed the strongest antiproliferative activity among a series of related honokiol thioethers and outperformed 5-fluorouracil in an HCT116 cell assay. Mechanistically, the compound was reported to inhibit **transcription and expression of Yes-associated protein 1**, causing G1-phase arrest and cell death, without activating the Hippo signaling pathway. It appears to be an **early research-stage experimental compound** described in the academic literature rather than a named clinical-stage asset or commercial product.

Other names

honokiol derivative 3k